Upcoming IPO with around 40 per cent GMP: Should you consider investing? Upcoming IPO with around 40 per cent GMP: Should you consider investing? In this IPO analysis, we take a closer look at Indo Farm Equipment Ltd and present you with exclusive details. Mandar Wagh / Tuesday, December 31, 2024 0 345 Article rating: 4.8 In this IPO analysis, we take a closer look at Indo Farm Equipment Ltd and present you with exclusive details. Read more
Skyrocketing success: This aerospace IPO gets fully subscribed within hours; have you boarded the flight? Skyrocketing success: This aerospace IPO gets fully subscribed within hours; have you boarded the flight? Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 140 per cent in revenue and 314 per cent in net profit. Mandar Wagh / Monday, December 23, 2024 0 452 Article rating: 5.0 Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 140 per cent in revenue and 314 per cent in net profit. Read more
Too many IPOs at a time: Should you invest in Carraro India IPO? Too many IPOs at a time: Should you invest in Carraro India IPO? Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 10 per cent in revenue and 67 per cent in net profit. Mandar Wagh / Friday, December 20, 2024 0 654 Article rating: 4.0 Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 10 per cent in revenue and 67 per cent in net profit. Read more
Ventive Hospitality IPO: A gateway to luxury growth Ventive Hospitality IPO: A gateway to luxury growth Between FY22 and FY24, it achieved a Compound Annual Growth Rate (CAGR) of 44 per cent in revenue and a remarkable 138 per cent in net profit. Mandar Wagh / Friday, December 20, 2024 0 448 Article rating: 4.5 Between FY22 and FY24, it achieved a Compound Annual Growth Rate (CAGR) of 44 per cent in revenue and a remarkable 138 per cent in net profit. Read more
Triple-digit CAGR pharma player hits the market: Should you invest? Triple-digit CAGR pharma player hits the market: Should you invest? Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 285 per cent in revenue and 472 per cent in net profit. Mandar Wagh / Friday, December 20, 2024 0 547 Article rating: 5.0 Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 285 per cent in revenue and 472 per cent in net profit. Read more